The increasing prevalence and economic impact of heart failure (HF) is a global epidemic and a significant concern in cardiovascular medicine. Currently, the primary approach to HF treatment focuses on reactive measures for those with established and symptomatic disease. However, the burden of HF will continue to rise unless effective strategies for prevention, both primary and secondary, are implemented. This includes promoting awareness of lifestyle choices that can modify risk factors for HF development (known as primordial prevention). The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) Guideline for the Management of HF introduces the concept of HF staging (illustrated in Figure 1). In 2021, the HFSA released a consensus statement, the Universal Definition and Classification of HF, which revises the stages to categorize individuals as A (at risk of HF), B (pre-HF), C (HF), and D (advanced HF).